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Background: GHB dependence is a growing health problem in several western countries, especially the
Netherlands. Attempts to stop using GHB are often followed by relapse shortly after successful detoxification.
Craving for GHB use and co-morbid psychiatric symptom levels are thought to be the major factors contributing to
the high relapse rates. Given its pharmacological profile, baclofen might prove an effective anti-craving agent for
patients with GHB dependence. The aim of the current study is to assess the potential of baclofen as an anti-craving
agent relapse prevention intervention in GHB dependent patients.
Methods/Design: In an open label non-randomized trial treatment with baclofen to a maximum of 60 mg/day will be
compared with treatment as usual (TAU) in recently detoxified GHB dependent patients (n = 80). The primary outcome
measure will be the level of GHB use. Secondary outcome measures are craving levels, psychiatric symptom levels and
quality of life. Questionnaires will be administered during 12 weeks of baclofen treatment and at follow-up (six months
after the start of treatment).
Discussion: It is hypothesized that baclofen treatment compared to TAU will be associated with significantly reduced
GHB use. In addition, we hypothesize that baclofen treatment will be associated with decreased craving and anxiety
levels, and higher quality of life. If results are in line with our hypotheses, further studies on the efficacy of baclofen
using placebo controlled designs and long term follow-up are warranted.
Trial registration: The Netherlands Trial Register with number NTR4528. Registered 19 April 2014.
Keywords: Baclofen, Gamma- Hydroxybutyrate, GHB dependence, Relapse, CravingBackground
GHB use is a growing public health issue in several
Western countries, including the Netherlands [1]. Recre-
ational use of GHB has gained popularity over the past
decades [2]. As a result, it’s addictive potential has be-
come more apparent [3]. Little is known about the exact
prevalence of chronic GHB dependence in the USA and
Europe due to the absence of surveillance and systematic
reporting mechanisms [4]. Nevertheless the number of
GHB users seeking help increased over the past years
[5]. For example, the number of GHB dependent pa-
tients admitted in addiction treatment facilities sharply* Correspondence: rama.kamal@novadic-kentron.nl
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unless otherwise stated.increased in the Netherlands, over the last five years
from 60 in 2008 to almost 800 patients in 2013 [6].
Gamma-hydroxybutyrate (GHB) is a short-chain fatty
acid that is an endogenous precursor and metabolite of
gamma-aminobutyric acid (GABA). GHB administered
systemically can cross the blood–brain barrier where it
acts both as neurotransmitter and a neuromodulator [7].
It has a plasma half-life of approximately 30–60 minutes
[8]. GHB has high affinity for the GABA-B receptor and
to a lesser extent for subtypes of the GABA-A receptor
[9]. GHB has impact as neuromodulator via both GABA-
ergic effects and direct effects on a wide variety of other
neurotransmitters, including glutamate, dopamine, sero-
tonin, noradrenaline, acetylcholine, opioids, and GABA
[10-12]. GHB has various therapeutic applications, like
general anesthesia [13], treatment of sleep disorders asThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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opioid withdrawal [16].
GHB tolerance occurs rapidly when used daily, inducing
physical dependence at higher doses. Discontinuation of
GHB can produce severe withdrawal symptoms as anxiety,
delirium with auditory and visual hallucinations, seizers,
and coma, which may be life threatening [17,18]. Recent
studies have shown safety of strategies for the detoxifica-
tion in GHB dependence, using tapering with pharma-
ceutical GHB or benzodiazepines [19]. Nevertheless, high
relapse rates hamper long-term recovery, despite psycho-
logical treatment and counseling. Forty-five percent of the
cases reporting to addiction care facilities had previously
been in treatment for GHB dependence [19]. Indeed, short-
term relapse rates up to 64% have been reported [20]. Self-
reported reasons for relapse include social pressure, craving
for and loss of control over GHB use and increased anx-
iety and depression after stopping GHB use [21].
Here we present a study protocol investigating the
potential of baclofen in relapse prevention and its anti-
craving properties in recently detoxified GHB dependent
patients. Baclofen is a high affinity GABA-B receptor
agonist with a half-life ranging from 2 to 6 hours [22].
The pharmacological overlap between baclofen and GHB
suggests that the relatively long-acting baclofen may serve
as a substitute for the short acting GHB. Moreover, baclo-
fen is thought to modify brain reward function, through
its indirect effects on dopamine, which has been suggested
to be a key neurotransmitter for craving [23-25]. Finally,
baclofen is thought to have anxiolytic effects through its
agonist effects on the GABA-B receptor [26]. Overall, it
could be speculated that baclofen may be effective in
relapse prevention in GHB dependent patients. Indeed,
animal data have shown beneficial effects of baclofen on
GHB self-administration in mice [27].
Aims and hypotheses
The primary aim of the current study is to assess the poten-
tial of baclofen to prevent relapse in recently detoxified
GHB-dependent patients. We hypothesize that administra-
tion of baclofen to GHB-dependent patients after detoxifica-
tion is associated with decreased relapse rates as compared
to treatment as usual (without baclofen). We also hypothe-
size that treatment with baclofen is associated with reduced
levels of craving for GHB and reduced psychiatric symptoms
levels, including anxiety, and increased quality of life. We
expect baclofen treatment to cause minimal side effects in
these patients. Finally, we expect a lower drop-out rate
from adjuvant therapy (TAU) in the intervention group.
Methods and Design
Study design
The design is of an open label non-randomized con-
trolled clinical study in six addiction care facilities in theNetherlands. The study is part of the Dutch national
GHB Monitor 2.0 and data collection will take place be-
tween May 2014 and December 2015. After successful
detoxification of GHB, patients will receive either baclofen
on top of treatment as usual (TAU+ baclofen) or treatment
as usual (TAU) only. Assignment is based on in- and exclu-
sion criteria and on patient preference (informed consent).
Ethical considerations
The study was approved by the Medical Ethics Committee,
Twente Medical School, Institute for Applied Scientific Re-
search (METC/14015.kam) study number NL40321.044.13.
Participants are informed about the trial and about the vol-
untary nature of their participation with both written and
verbal communications. Participants are only included fol-
lowing the provision of informed consent.
Participants
Recruitment
Participants are GHB dependent patients in treatment
for detoxification at six participating addiction care facil-
ities. These GHB dependent patients will be informed by
their physician about the possibility to participate in the
current study before GHB detoxification. The physician
will inform the research nurse per centre on potential
participants for the study, who will provide further study
information to the patients after the detoxification. After
informed consent, a research physician will perform the
medical screening. The intervention group will be com-
pared with two control groups: recently detoxified GHB
dependent patients included in the Dutch national GHB
Monitor 2.0, but that do not want to use baclofen (TAU
only); and a matched historical control group from our
previous work on GHB dependence (n = 274) of whom
follow-up data are available [20]. The historical control
group will be matched on age, gender, GHB use (dose
and years), and number of detoxification attempts.
In- and exclusion criteria
Patients are eligible to participate if GHB dependence
(according to the DSM-IV general criteria of dependence)
is their primary diagnosis [28] and their age is at least
18 years. All participants should be able to read and speak
the Dutch language. Patients with any current somatic or
psychiatric safety concerns are excluded. Exclusion criteria
are liver cirrhosis and impaired renal function (as indicated
by aspartate aminotransferase (AST)), alanine transamin-
ase (ALT), or gamma-glutamyl transferase ((GGT) level >3
times the upper limit of normal (ULN); bilirubin > ULN;
serum creatinine >ULN), unstable hypertension, unstable
diabetes mellitus, seizure disorder including patients cur-
rently taking anticonvulsants, and pregnancy. Patients ex-
periencing current severe mood disorder (bipolar disorder
or major depressive disorder), current psychotic disorder
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patients suffering Parkinson’s disease will be excluded too.
Co-current use of anxiolytics, stimulants or hypnotics will
not be permitted.Sample size calculation
To date, there are no published studies on the effect of
baclofen on relapse in GHB dependent patients. There-
fore, we used the results of previous studies on the effect
of baclofen in alcohol dependent patients and our previ-
ous work on GHB dependence, in order to estimate the
required sample size. Two RCTs showed that baclofen
was superior to placebo in increasing abstinence rates in
alcohol dependent patients: 70% (14 out of 20) versus
21% (4 out of 19) within a period of 30 days [29] and
71% (30 out of 42 p) versus 29% (14 out of 42) within a
period of 12 weeks [30]. These results indicate a po-
tential increase in abstinence of 42–49% with baclofen
treatment for alcohol dependence. Results of the previ-
ous national GHB project stated that 36% of the patients
succeeded to avoid relapse in GHB within a period of
3 months after detoxification without any medical inter-
ventions [20]. Therefore, we will consider a percentage
of importance difference in baclofen effect in the GHB
dependent participants of 34% between the Baclofen +
TAU group and the TAU only or the matched control
group with an expected abstinence rate with baclofen
of 70% as in the alcohol studies and of 36% without
baclofen.
We used the following formula comparing two propor-
tions to calculate the sample size, n = [(Zα/2 + Zβ)2 × {(p1
(1-p1) + (p2 (1-p2))}] / (p1 - p2)2, n = [(1.96+ 0.84)2 × {(0.7
(1–0.7) + (0.36 (1–0.36))}] / (0.34)2, according to Dr. Steve
Brooks sample size calculator, Exeter Initiative for Statis-
tics. The calculation estimates that the minimal total sam-
ples size of 30 patients per group would be sufficient to
detect a clinical difference of 34% in two-tailed z-test of
proportions (α = 0.05, β=0.80). In the alcohol studies and
our previous work with GHB inpatients an attrition rate
of 13–15% was reported. We anticipate a slightly higher
drop-out rate of 25%, due to the outpatient component of
the baclofen treatment. Therefore we will include 40 par-
ticipants in the baclofen treatment group.Study intervention
Baclofen intervention
Clinical trials on baclofen for alcohol dependence treat-
ment have used baclofen at a dose of 30 mg ⁄d [29-31]
over 30 to 120 days. This is within the low therapeuticTable 1 Baclofen dose in mg/week
Week 1 2 3 4 5 6 7
Doses a day 15–30 45–60 45/60 45/60 45/60 45/60 45/60range for muscle spasms. However, Garbutt and col-
league’s [32] suggested that 30 mg of baclofen per day
may be an insufficient dose for some patients to achieve
abstinence. Additionally, baclofen effectiveness for GHB
dependence could be smaller, since tolerance may occur
due to recent abuse of GHB and a possible substitution
function (as treatment will be started immediately after
detoxification).
Based on these results and the unpublished results of
a small dose finding experimental treatment study in
our treatment center, where patients reported limited
effect of baclofen 30 mg per day, we decided to adminis-
trate a dose of 45 mg to a maximal dose of 60 mg per
day orally to avoid the risk of (co) intoxication. In this
study baclofen will be administrated orally three times
daily as usually recommended [22] and started with a
total dose of 15 mg per day. During the first 10 days
baclofen will be gradually increased with 15 mg per day
every 3 days up to the chosen minimum dose of 45 mg,
or a maximum dose of 60 mg in case no effect is reported
at 45 mg after 2 weeks. This dose will subsequently be
maintained for a period of 10 weeks. Successively, baclo-
fen will be tapered off to 0 mg in 2 weeks (see Table 1).
Patients will be asked to avoid abrupt termination of bac-
lofen and will be guided by their physician to avoid com-
plications of baclofen withdrawal. Patients who wished to
continue the baclofen treatment will be offered an out-
patient counselling and medication by their physician for
another 3 months.
Compliance will be assessed based on self-report, urine
test for GHB, and empty pill counts. The physician will
make use of the BRENDA method, a psychosocial program
designed to enhance medication and treatment compliance
[33,34]. In case of GHB use during baclofen treatment, par-
ticipants are expected to contact the research physician. In
case of relapse, immediate cessation of treatment will be
considered to avoid intoxication hazards.Treatment as usual (TAU)
Patients included in the current study will undergo the
usual treatment provided by their addiction treatment cen-
ter (TAU). These can vary from short individual behavioral
treatment intervention, inpatient treatment, Community
reinforcement therapy, or extensive multidimensional ther-
apy (like MDFT) with attention to psychological, social, re-
lation, financial, and medical problems. During the study
the psychological interventions applied will be monitored.
For the historical control group, reports on the adjunct psy-
chological treatment interventions applied are unavailable.8 9 10 11 12 13 14 15
45/60 45/60 45/60 45/60 45/60 30–45 15–30 15–0
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Primary outcome measures
The primary study outcome is the relapse rate, in other
words the level of GHB use as indexed by the total num-
ber of abstinent days, the duration of continued abstin-
ence after detoxification (CAD), time before relapse, and
intensity of substance use over a period of 3 and
6 months (Timeline Follow-back Method).
Secondary outcome measures
The secondary outcomes as listed below are;
The craving level, as indexed by self-report using the
Desire for Drugs Questionnaire (DDQ) and a visual
analogue scale (VAS). The DDQ is validated instrument
[35] which measures an instant desire, triggered by
internal or external cures (instant craving). Franken and
colleagues [35] identified three factors as underlying
dimensions, namely ‘desire and intention’ (seven items),
‘negative reinforcement’ (four items), and ‘control’ (two
items) with a scale from 1 (totally disagree) to 7 (totally
agree). The total score exists of 14 items with a sum
score between 14 and 98 [35]. In addition to that
patients were asked to rate craving for GHB by means of
a visual analogue scale (VAS) on a Vertical line from no
craving at all (at the bottom) with a score of 0, to
extremely strong craving (at the Top) with a score of
100. The result is a score on a continuous scale ranging
from 0 to 100.
A change in psychiatric symptoms will be measured by
means of the Mini International Neuropsychiatric
Interview-plus (MINI-plus) and Depression Anxiety
Stress scale (DASS). A trained therapist or physician will
apply the MINI-plus. It is a structured interview to
assess the main Axis I psychiatric disorders based upon
the DSM–IV and ICD-10 criteria. It is used to determine
current and lifetime psychiatric disorders [36]. The
MINI is shown to have good psychometric properties
and is reliable for the detection and classification of
psychiatric comorbidity [37]. The DASS self-report will
be used to measure psychiatric symptom levels and the
related negative emotional states along the 3 axes of
depression, anxiety and stress. It is a 21-item self-report
instrument. Participants are asked to use a 4-point
severity scales to rate the extent to which they have
experienced each state over the past week. Scores for
Depression, Anxiety and Stress are calculated by
summing the scores for the relevant items. For each
scale threshold values are proposed and are interpreted
in 5 severity intensities: normal, mild, moderate, severe
and extremely severe. Thresholds as (for Depression ≥
21; for Anxiety ≥15; for Stress ≥ 26) indicate a severe or
extremely severe distress state [38,39].
The EuroQol-5D (EQ-5D) will be used to measure
changes in patients’ health-related quality of life. For theoverall quantification of health status as a single index
we will use the standard EQ-5D classification system
developed by the EuroQol Group [40]. The EQ-5D is a
widely used multi-attribute system available to deter-
mine health state preferences (utilities). It is a simple
self-report instrument which assesses 5 domains of
general health and functioning: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. This
is along a 3-point scale (1 = no problems, 2 = some
problems and 3 = extreme problems). Based on the
descriptive classification of the EQ-5D system a
preference index (utility) can be estimated that expresses
the overall preference of the classified health status [41]
[the Netherlands algorithm will be used to calculate the
index]. This EQ-5D index measures objective quality of
life and is a societal-based numerical quantification of
the patients’ health status in a scale from-.594 to 1
(perfect health), 0 is (as bad as being dead). In addition,
participants will be asked to rate the overall health
related quality of life, by means of a visual analogue scale
(EQ-5D VAS). The VAS is a 100-mm vertical line from
worst (0) to optimal of health (100). The EQ-5D VAS
represents the subjective quality of life.
Safety of baclofen will be assessed by the number and
intensity of reported side effects, using weekly report of
adverse effects on a checklist and standardized medical
assessments. The side-effects checklist is based on
published side effects of baclofen in the treatment of
Multiple Sclerosis [42]. Side-effects are partly self-
monitored (21 items) and partly observed (8 items) by a
doctor or nurse practitioner. Every item is scored on a
five-point Likert scale: never (0), seldom (1), sometimes
(2), frequently (3) or always (4). Examples of items are
vomiting, nausea and diarrhea. The checklist also
contains 5 parameters measured by a doctor or nurse
practitioner. Examples of parameters are body temperature
and heart rate frequency.
Additional measures
Addiction physicians will be asked to monitor
withdrawal symptoms when tapering baclofen, using
standard questions. These include a short check of
the most reported withdrawal symptoms in the
literature [43,44].
We will monitor the use of other substances over the
last thirty days (number of days and quantity) using
section 1 of the Measurement of Addicts for Triage and
Evaluation (MATE) before and after detoxification and
at follow up (3 months). The MATE is a Dutch
instrument designed as an aid in the diagnosis of
clinically relevant patient characteristics in substance use
disorders according to the DSM-IV axes [45].
At 6 month period we will also report on the
needed period of treatment with baclofen to maintain
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and craving assessment (DDQ, VAS) within the interven-
tion group between those who used baclofen for 3 month
only and those who choose to continue the treatment
further.
Procedure and data collection
Patients in all treatment conditions (baclofen + TAU
or TAU only) will be assessed by research assistants
identically in the following time points. Before detoxi-
fication, the intensity of GHB abuse (MATE), Quality
of life (EQ-5D) and psychiatric comorbidity (DASS)
will be assessed. At the end of the detoxification
treatment (baseline) and at follow up (three months
after start of detoxification) craving (VAS, DDQ), psy-
chiatric comorbidity (MINI plus, DASS), and Quality
of life (EQ-5D) will be assessed.
The addiction physician will monitor the participants
in the baclofen condition during regular medical check-
ups for potential side effects (side effect checklist) and
craving (VAS, DDQ), see Table 2. During the follow-up
(six months after start of detoxification) the DDQ, DASS,
MINI-plus, EQ-5D will be repeated. In summery self-
report questionnaires will be administered at the start of
detoxification; start of baclofen treatment (week 0), baclo-
fen titration and stabilization (week 1 + 2) and mainten-
ance treatment (week 3–12). Add to that, three months
after the end of the baclofen treatment, a follow-up
measurements will take place. The research assistant will
build up an online Client Record Form from all theTable 2 Time measurements








Medical consult 2x 2x 2x x x
Baclofen (mg) 0 15–30
Baclofen Side effect x 2x 2x x x
VAS xx x x x x
DDQ xx x x x x
Baclofen withdrawal checklist
Timeline follow back
xx = baclofen group and control group TAU only.
x = baclofen group.
T0 = end of GHB detoxification.
T1 = start baclofen treatment.
T2 = follow-up TAU only and end of baclofen therapy.
T3 = follow-up baclofen group.questionnaires filled in by the patients. A summary of the
medical records will be added by the physician to the elec-
tronic patient file.
Statistical analyses
Descriptive analysis will be executed for all measure-
ments and will include the mean, SD and frequen-
cies of events with confidence intervals. Descriptive
statistics will be used to compare the basic charac-
teristics of the participants in the experimental
group and the control groups. To assess any differ-
ence in relapse rates between the experimental group
and the control groups (TAU group and matched
historical group) at 3 month after detoxification Pearson
Chi-squared test will be used for the dichotomous
abstinence rates. ANOVA will be carried out on continu-
ous variables, such as the total number of abstinent days,
the maximum duration of continued abstinence, time be-
fore relapse (relapse defined as ≥ 3 times GHB use per
day, for 2 subsequent days), and level of substance use
over a period of 3 months. At 6 months period partici-
pants who continued baclofen will be compared to those
who have stopped with baclofen (after 3 month) on
relapse into GHB abuse or abstinence corrected for
craving. The numbers of patients maintaining abstinence
will be analysed with the intention-to-treat principles. The
difference in craving will be analysed by MANCOVA at
3 months between groups (abstinent experimental versus
abstinent TAU or relapsed TAU) with DDQ and VAS








x x x x x
45– 60 30–45 30–15 15–0 0
x x x
x x xx x
x x xx x
x x x
xx x
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craving in time during the baclofen treatment will be ana-
lysed via repeated measures MANOVA. By means of
MANCOVA at 6 months after detoxification the differ-
ence in craving among participants who are still using
baclofen and those who have discontinued baclofen will
be analysed corrected for craving after 3 months. The
effect of baclofen on the psychiatric symptoms levels
(DASS, MINI) and also quality of life (EQ–5D) will be
analyzed similarly as for craving at 3 and 6 months. The
effects of the different TAU approaches as potential con-
founders will be tested in a sensitivity analyses (changing
one-factor-at-a-time) in an linear regression including TAU
per center as covariates.
Safety of baclofen, as assessed by the number and
intensity of reported side effects, will be analyzed in
the following categories: acceptable or unacceptable
adverse effect, clinically significant deterioration, and
relocation. In all analyses socio-demographic charac-
teristics such as age and gender will be considered
as co-variates in the analysis. Two-sided p-value of >
.05 is considered statistically significant. The statis-
tical software package SPSS will be used for all the
computations.Discussion
This study protocol presents the design of an open label
clinical trial evaluating the efficacy of baclofen to pre-
vent relapse, reduce craving and anxiety, and to assess
the safety profile of baclofen in GHB dependent patients.
To date, there are no reports on the potential of baclo-
fen to prevent relapse in GHB dependent patients. We
expect that baclofen will increase abstinence rates, re-
duce craving and will be well tolerated. In addition, bac-
lofen may improve psychiatric symptoms such as anxiety
and depression, as suggested in several clinical trials in
alcohol-dependent individuals [29,30,46].
Several risks of baclofen use are taken into account in
the current study. In patients with neuropsychiatric dis-
orders, such as schizophrenia, severe depression, mania,
Parkinson’s disease and cerebrovascular diseases, exacer-
bations of these conditions may occur, when the dose of
baclofen is rapidly increased. It may lower the threshold
for seizures in epileptic patients [42]. To limit these risks
in the current trial, baclofen will be uploaded gradually,
over a period of minimally 10 days. Moreover, patients
previously diagnosed with any of the mentioned diseases
will be excluded from the study.
Abrupt discontinuation of baclofen, when used for
several months, can be associated with a withdrawal
syndrome which resembles benzodiazepine and alco-
hol withdrawal. Several symptoms are reported such
as hallucinations, fever, confusion, delirium, agitation,insomnia, and muscle stiffness and spasms [47].
Therefore, patients will be advised to taper down
slowly when discontinuation is needed.
Intoxication with baclofen has been reported in
doses above 100 mg [48]. This risk increases if pa-
tients combine baclofen with GHB. Intoxication is not
expected when baclofen is administered at a low dose
(<30 mg per gift), as applied in the current study. Patients
will however, be informed repeatedly of this potential risk
and the treatment will be discontinued immediately in
case of relapse.
The current study does have several limitations. First,
the study is not randomized, nor placebo controlled.
However, we will compare patients receiving baclofen
with a control group matched for gender, age and the
pattern of GHB use, in order to control for potential
confounding factors. Second, the accompanying treat-
ment as usual (TAU) is not identical in all participating
addiction care facilities. This may confound our results.
The impact of TAU will be checked with a sensitivity
analysis compare patients’ results from the different cen-
ters conforming the add-on baclofen effect.
Given these methodological limitations the current
study should be considered explorative in nature. Given
the currently rather limited information from both pre-
clinical and clinical studies of GHB such an explorative
approach seems justified. We would also like to test the
GHB substitution effect of baclofen (as a GABA-B agon-
ist) hypothesis. It is important to evaluate of this effect is
clinically recognized and obvious for the participants,
and may define placebo use as non-beneficial. We need to
be able to determine the margins of the required treat-
ment dose. All forgoing justify this setup of an open label
trail before a large placebo controlled randomized trial.Implications for practice
If our study confirms the potential of baclofen to reduce
relapse and craving without serious adverse events in
GHB-dependent patients, this warrants large scale ran-
domized controlled trials in order to draw more firm
conclusions. If baclofen showed to have beneficial effects
on psychiatric symptoms in these patients, baclofen
might be specific interest for the treatment of those
GHB dependent patients with co-morbid high levels of
anxiety and depression.Competing interests
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